Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jan 25, 2025. (Total: 235671Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 10 (of 10 Records)

Query Trace: Disease Progression and MUT[original query]
Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
Leukemia 2013 Jan 27 (1): 41-7.
Jenkinson S, Koo K, Mansour M R, Goulden N, Vora A, Mitchell C, Wade R, Richards S, Hancock J, Moorman A V, Linch D C, Gale R
GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Annals of hematology 2015 Feb 94 (2): 211-21.
Hou Hsin-An, Lin Yun-Chu, Kuo Yuan-Yeh, Chou Wen-Chien, Lin Chien-Chin, Liu Chieh-Yu, Chen Chien-Yuan, Lin Liang-In, Tseng Mei-Hsuan, Huang Chi-Fei, Chiang Ying-Chieh, Liu Ming-Chih, Liu Chia-Wen, Tang Jih-Luh, Yao Ming, Huang Shang-Yi, Ko Bor-Sheng, Hsu Szu-Chun, Wu Shang-Ju, Tsay Woei, Chen Yao-Chang, Tien Hwei-Fa
Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
Medical science monitor : international medical journal of experimental and clinical research 2014 20 2666-76.
Zhang Wen-Qian, Li Tong, Li H
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
The Lancet. Oncology 2015 Jun 16 (6): 686-94.
Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu, Kristeleit Rebec
Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
Oncology 2018 10 96 (1): 51-58.
Hong Sook-Hee, An Ho Jung, Kim Kihyun, Lee Seung Sei, Lee Yun-Gyoo, Yuh Young-Jin, Park I Cheon, Chae Yee Soo, Jang Tae-Won, Kang Jin-Hyou
ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
Radiation oncology (London, England) 2020 Jul 15 (1): 184.
Kim Nalee, Kim Se Hoon, Kang Seok-Gu, Moon Ju Hyung, Cho Jaeho, Suh Chang-Ok, In Yoon Hong, Chang Jong H
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Clinical cancer research : an official journal of the American Association for Cancer Research 2022 7 28 (19): 4240-4247.
Jung Hyun Ae, Park Keon-Uk, Cho Sanghee, Lim Jinyeong, Lee Keun-Wook, Hong Min Hee, Yun Tak, An Ho Jung, Park Woong-Yang, Pereira Sergio, Ock Chan-Young, Keam Bhums
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
European journal of cancer (Oxford, England : 1990) 2023 4 187 15-24.
Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola, Chiara Boccaccio, Gianmarco Ricagno, Filippo Ghelardi, Giovanni Randon, Giuseppe Leoncini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietranton
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
ESMO open 2024 5 9 (5): 102964.
L Buisseret, Y Bareche, D Venet, E Girard, A Gombos, P Emonts, S Majjaj, G Rouas, M Serra, V Debien, E Agostinetto, S Garaud, K Willard-Gallo, D Larsimont, J Stagg, F Rothé, C Sotiri
Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 1 .
Min-Min Shao, Yue-Ping Xu, Jin-Jing Zhang, Mao Mao, Meng-Chuan Wa
TOP